Amarantus BioScience Holdings, Inc.
AMBS
Other OTC0.00
USD
- -
- -
CIK
0001424812
ISIN
US02300U2050
CUSIP
02300U205
Return %
Stock
S&P500
1Y
-66.67
26.53
3Y
-90.91
76.60
5Y
-98.75
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- John Wesley Commissiong
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 45 Wall Street New York City NY United States of America 10005
- IPO Date
- Sep 10, 2010
- CIK
- 0001424812
- Website
- amarantus.com
- Similar Companies
- Business
- Amarantus BioScience Holdings, Inc. is a biotechnology company engaged in the development of therapeutic and diagnostic products primarily focused on diseases associated with neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s core offerings include its Engineered Skin Substitute (ESS) program for severe burns and rare pediatric skin diseases; a Phase 2b-ready small molecule, Eltoprazine, for Parkinson’s disease levodopa-induced dyskinesia, adult ADHD, and Alzheimer's aggression; and a range of diagnostic assays such as MSPrecise®, a next-generation DNA sequencing assay for relapsing-remitting multiple sclerosis, the LymPro Test® for Alzheimer's disease, and NuroPro for Parkinson’s diagnosis. Additionally, Amarantus holds intellectual property for neurotrophic factors including mesencephalic-astrocyte-derived neurotrophic factor (MANF), which it is developing for brain and ophthalmic disorders. The company operates globally, with headquarters in New York, New York, and a significant laboratory presence in Camden, New Jersey. In recent years, Amarantus has made strategic moves to expand its portfolio and operational base. Notably, it acquired DioGenix, a specialized neuro-diagnostics company, for its pipeline of immune-mediated neurological disease diagnostics including products for multiple sclerosis, neurosarcoid, neuromyelitis optica, paraneoplastic disease, and amyotrophic lateral sclerosis (ALS). This acquisition forms the foundation of Amarantus Diagnostics, enhancing its capabilities in neurodiagnostic testing. In 2020, the company also acquired a majority interest in Hempori, Inc., a CBD wellness company, adding a cash flow-generating segment to its operations. The Engineered Skin Substitute program has progressed into Phase 2 clinical studies under a CRADA agreement with the U.S. Army and is advancing preparations for pivotal trials targeting rare pediatric diseases. Amarantus also maintains a founding membership in the Global Brain Health Coalition, aligning with its strategic focus on brain health and neurodegeneration. Founded in 2008, Amarantus BioScience Holdings focuses on biotechnology research and development, targeting orphan diseases and complex neurological conditions. Its products and services serve clinical and research markets, aiming to improve diagnostic precision and develop innovative therapeutics. The company’s portfolio addresses unmet medical needs in neurodegenerative diseases, acute and chronic neurological disorders, and regenerative medicine applications. Through acquisitions, licensing agreements, and in-house research, Amarantus continues to build integrated diagnostic and therapeutic platforms designed for global healthcare markets.
Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
Contrasting Amarantus Bioscience (OTCMKTS:AMBS) & Progyny (NASDAQ:PGNY)
Contrasting Pediatrix Medical Group (NYSE:MD) & Amarantus Bioscience (OTCMKTS:AMBS)
Head to Head Comparison: Amarantus Bioscience (OTCMKTS:AMBS) & PACS Group (NYSE:PACS)